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(citalopram, fluoxetine, paroxetine, and sertraline) and
venlafaxine in US managed care plans.
METHODS: Symmetry Health Data Systems’ Episode
Treatment Group methodology was applied to the Phar-
Metrics Integrated Outcomes Database to identify adult
subjects (18 years) diagnosed with depressive disorder
and treated with one of the study medications between
January 1, 1998 and June 30, 1999. Diagnosis codes and
prescription claims records were used to identify the
existence of comorbidities and coprescribed therapies.
Descriptive statistics were used to characterize rates of
comorbidities and coprescribing, and parametric and non-
parametric methods (ANOVA and chi-square, with correc-
tions for multiple comparisons) were used to compare rates
across medication cohorts.
RESULTS: Twelve thousand twenty six patients met the
inclusion criteria. The study cohorts were similar in terms
of demographics. Most subjects (79%) had no other
mental health diagnoses. Among those who did, anxiety
(14%) and substance abuse (6%) were most common;
paroxetine and sertraline patients had the highest rates of
these comorbidities. Hypertension (17%) and hyperlipi-
demia (12%) were the most prevalent non-mental health
comorbidities. Citalopram- and paroxetine-treated pa-
tients had the highest rates of these conditions. Coronary
artery disease was more prevalent in the paroxetine and
sertraline cohorts (p  .001) compared to other study co-
horts. Citalopram-treated patients had the highest rate of
prior psychotherapy (30%). Most subjects (90%) had no
prior use of antidepressant medications, although citalo-
pram- (11%) and venlafaxine-treated (15%) patients had
higher rates prior to index diagnosis. The most com-
monly coprescribed agents for study patients were anxi-
olytics (15%) and codeine (15%).
CONCLUSIONS: Depressed patients treated with newer
antidepressant drugs may be complex in their clinical
presentation and management. Clinicians and payers
should be aware of comorbidity and coprescribing rates
to provide optimal care for these unique populations.
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OBJECTIVE: To determine the change in schizophrenia-
related total direct medical costs following initiation of
olanzapine or risperidone therapy.
METHODS: The MEDSTAT Group’s MarketScan data-
base was used to obtain data on inpatient, outpatient,
and prescription drug claims. This database represents
the health care experiences of individuals employed in
large organizations in the US, as well as the dependants
of those individuals. Data between 1996 and 1999 were
analyzed. Patients with a diagnosis of schizophrenia, and
initiating either olanzapine or risperidone pharmacother-
apy were included in the study data set. Inpatient, outpa-
tient, and medication costs were assessed for one year
prior to, and one year following the initiation of olanzap-
ine or risperidone.
RESULTS: A total of 162 patients on olanzapine and 119
patients on risperidone were identified. There were no
significant differences between the two groups in either
patient demographics, or resource use in the year prior to
initiation of the medications. However, patients initiating
on olanzapine incurred higher total schizophrenia-related
direct medical costs in the year prior to initiation. The
mean initial dose of olanzapine was 11.5 mg, while the
mean initial dose of risperidone was 4.5 mg. For patients
initiating on olanzapine, there was no significant differ-
ence in the change in schizophrenia-related total direct
medical costs ($4,337.37 to $5,216.17; p  0.45) com-
pared to the costs in the year prior to initiation. This is
because the higher medication costs in the treatment pe-
riod were partially offset by lower inpatient costs associ-
ated with olanzapine. For patients initiating on risperi-
done, there was a statistically significant increase in
schizophrenia-related total direct medical costs ($2,751.25
to $4,995.01; p  0.04) compared to the costs in the year
prior to initiation.
CONCLUSION: The results of this study demonstrate
that while initiation of treatment for schizophrenia with
olanzapine is not associated with higher total schizophre-
nia-related direct medical costs, initiation with risperi-
done is associated with significantly higher total schizo-
phrenia-related direct medical costs over one year.
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OBJECTIVE: To assess the frequency and management
of extrapyramidal symptoms (EPS), sexual dysfunction
related adverse events (SD-RAEs) and weight changes
which may impede optimal outcomes in schizophrenic
patients under antipsychotic treatment and to perform an
economic evaluation.
METHODS: A cross-sectional study was carried-out by
61 Spanish psychiatrists (the EIRE Study Group). Outpa-
tients meeting DSM-IV criteria for schizophrenia and tak-
ing a single atypical antipsychotic (olanzapine, quetiapine
or risperidone) for at least four weeks were evaluated. EPS,
SD-RAEs and weight changes were assessed using a modi-
fied-UKU scale, which included a question for assessing
management of adverse events. Cost of antipsychotic and
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EPS therapies obtained at wholesaler prices in 2001 were
used to perform a cost-effectiveness analysis comparing
the cost per patient free of EPS between drugs.
RESULTS: Five hundred five evaluable patients were as-
sessed. The average doses were those seen commonly in
the clinical setting: 13.5 mg/d (OLAN), 360.5 mg/d (QUE)
and 5.3 mg/d (RIS). Tolerability and economic evaluation
outcomes for olanzapine (n  228), quetiapine (n  43)
and risperidone (n  234) were: 35.8%, 39.5% and
55.1% with EPS (chi2: p  .05 risperidone vs. olanzapine);
35.3%, 18.2% and 43.2% with SD-RAEs (chi2: p  .05
risperidone vs. quetiapine); 74.5%, 13.5% and 53.4%
with weight gain (chi2: p  .05 risperidone & olanzapine
vs. quetiapine); daily therapy cost was 3.67, 2.72 and
1.96 euros; daily cost per patient without EPS was 5.72,
4.38 and 4.50 euros. EPS and SD-RAEs were dose-related
but weight gain was not. SD was more frequent in men.
Add-on therapy for EPS was required by 20.3%, 16.4%
and 7.1%, respectively of risperidone-, olanzapine- and
quetiapine-treated patients. SD and weight changes modi-
fied psychiatrist-patient management in only 17.2%,
10.2% and 0.0%, and in 2.1%, 9.0% and 0.0%, respec-
tively.
CONCLUSION: EPS, SD-RAEs and weight changes are
common side effects with atypical antipsychotics. Cost
per patient without EPS is higher with olanzapine than
with risperidone or quetiapine.
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OBJECTIVE: Attention Deficit Hyperactivity Disorder
(ADHD) is a condition that affects both children and
adults. Although behavioral aspects of this disorder are
well documented, little is known about associated medi-
cal costs. This study investigates the extent to which
ADHD imposes a financial burden from the perspective
of the beneficiary’s employer/third party payer.
METHODS: The data source is an administrative claims
database for the employed population of a national, For-
tune 100 manufacturer. It includes medical, pharmaceuti-
cal, and disability claims for employees, spouses, depen-
dents, and retirees for 1996–1998 (n  100,000). The
research sample consisted of individual patients with one
or more medical or disability claim for ADHD (N 
1,308). Resource utilization in the ADHD sample was
compared with that of a matched sample of the employ-
ers'overall beneficiary population. The matching criteria
were age, gender, state, and employment status.
RESULTS: The analysis included both direct (medical
and pharmaceutical) and indirect (disability and sporadic
absenteeism) costs. Average annual costs were $2,172 for
ADHD patients, and $730 for the matched controls. To-
tal costs for ADHD patients were three times those for
the controls. Thirteen percent of all direct and indirect
costs associated with ADHD patients could be attributed
primarily to the treatment of ADHD. Eighty-one percent
of ADHD patients had office visits in 1998, versus forty-
eight percent of the matched controls.
CONCLUSION: Based on these findings, resource utili-
zation by ADHD patients is substantially greater than
that of individuals without ADHD. Increased health-care
costs are due to medical interventions for ADHD and as-
sociated co-morbidities. Thus, ADHD is associated with
a significant financial burden for employers.
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OBJECTIVES: Relatively little data exists to estimate the
true burden of manic episodes on health-care systems,
and information on the therapeutic strategies used is
lacking. This study was undertaken to identify the treat-
ment strategies chosen and to assess the cost of treating a
manic episode for bipolar patients in a real-world setting.
METHODS: A multi-centre retrospective study over a
three-month period. Data were collected from hospital
records of patients who had to be hospitalized for a
manic episode between 1997 and 1999. Health-care re-
source utilisation (hospitalization, nursing home, medica-
tions and laboratory tests) was assessed, direct costs were
calculated, and treatment strategies analysed.
RESULTS: A total of 137 patients’ files (51.8% female,
mean age  35 years) were reviewed. Data on 185 hospi-
talizations were collected among which 28% of patients
had more than one hospitalization. The breakdown of
treatment strategies at D30 of hospitalization was as fol-
lows: neuroleptic and mood-stabiliser, 64% of patients;
neuroleptic alone or in association without mood-stabi-
liser, 18%; mood-stabiliser alone or in association with-
out neuroleptic, 14%; strategy without mood-stabiliser
or neuroleptic, 4%. After discharge, the breakdown of
these strategies was respectively as follows: 62%; 14%;
22%, and 2%. The mean number of days spent in hospi-
tal was 47 over the study period. On average patients had
received 4.9 medications at hospital and 3.4 in the com-
munity. The mean direct cost incurred over the three-
month study period was 22 297 Euros. The breakdown
of the cost per patient for the three-month data period is
as follows: hospitalization 98.6%; rehabilitation 0.6% (9
patients out of 137); visits 0.4%; medication 0.3%; labo-
ratory tests  0.01%.
CONCLUSION: These results confirm that the costs of
treating a manic episode are high, and overwhelmingly
due to the cost of hospitalization.
